194 related articles for article (PubMed ID: 30886310)
1. RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy.
Yoo B; Jordan VC; Sheedy P; Billig AM; Ross A; Pantazopoulos P; Medarova Z
Sci Rep; 2019 Mar; 9(1):4712. PubMed ID: 30886310
[TBL] [Abstract][Full Text] [Related]
2. RNAi mediated silencing of STAT3/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors.
Ganesh S; Kim MJ; Lee J; Feng X; Ule K; Mahan A; Krishnan HS; Wang Z; Anzahaee MY; Singhal G; Korboukh I; Lockridge JA; Sanftner L; Rijnbrand R; Abrams M; Brown BD
Mol Ther; 2024 Jun; 32(6):1895-1916. PubMed ID: 38549376
[TBL] [Abstract][Full Text] [Related]
3. Single dual-specific anti-PD-L1/TGF-β antibody synergizes with chemotherapy as neoadjuvant treatment for pancreatic ductal adenocarcinoma: a preclinical experimental study.
Zhang H; Chen J; Bai J; Zhang J; Huang S; Zeng L; Zhou P; Shen Q; Yin T
Int J Surg; 2024 May; 110(5):2679-2691. PubMed ID: 38489548
[TBL] [Abstract][Full Text] [Related]
4. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
[TBL] [Abstract][Full Text] [Related]
5. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice.
Peran I; Dakshanamurthy S; McCoy MD; Mavropoulos A; Allo B; Sebastian A; Hum NR; Sprague SC; Martin KA; Pishvaian MJ; Vietsch EE; Wellstein A; Atkins MB; Weiner LM; Quong AA; Loots GG; Yoo SS; Assefnia S; Byers SW
Gastroenterology; 2021 Mar; 160(4):1359-1372.e13. PubMed ID: 33307028
[TBL] [Abstract][Full Text] [Related]
6. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.
Koikawa K; Kibe S; Suizu F; Sekino N; Kim N; Manz TD; Pinch BJ; Akshinthala D; Verma A; Gaglia G; Nezu Y; Ke S; Qiu C; Ohuchida K; Oda Y; Lee TH; Wegiel B; Clohessy JG; London N; Santagata S; Wulf GM; Hidalgo M; Muthuswamy SK; Nakamura M; Gray NS; Zhou XZ; Lu KP
Cell; 2021 Sep; 184(18):4753-4771.e27. PubMed ID: 34388391
[TBL] [Abstract][Full Text] [Related]
7. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
[TBL] [Abstract][Full Text] [Related]
9. PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer.
Wang K; Yan L; Qiu X; Chen H; Gao F; Ge W; Lian Z; Wei X; Wang S; He H; Xu X
Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167236. PubMed ID: 38740225
[TBL] [Abstract][Full Text] [Related]
10. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
Winograd R; Byrne KT; Evans RA; Odorizzi PM; Meyer AR; Bajor DL; Clendenin C; Stanger BZ; Furth EE; Wherry EJ; Vonderheide RH
Cancer Immunol Res; 2015 Apr; 3(4):399-411. PubMed ID: 25678581
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma.
Du B; Wen X; Wang Y; Lin M; Lai J
Int Immunopharmacol; 2020 Sep; 86():106694. PubMed ID: 32570034
[TBL] [Abstract][Full Text] [Related]
12. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
13. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis.
Ho TTB; Nasti A; Seki A; Komura T; Inui H; Kozaka T; Kitamura Y; Shiba K; Yamashita T; Yamashita T; Mizukoshi E; Kawaguchi K; Wada T; Honda M; Kaneko S; Sakai Y
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188035
[TBL] [Abstract][Full Text] [Related]
14. Exploring in vivo combinatorial chemo-immunotherapy: Addressing p97 suppression and immune reinvigoration in pancreatic cancer with tumor microenvironment-responsive nanoformulation.
Lo YL; Li CY; Chou TF; Yang CP; Wu LL; Chen CJ; Chang YH
Biomed Pharmacother; 2024 Jun; 175():116660. PubMed ID: 38701563
[TBL] [Abstract][Full Text] [Related]
15. T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer.
Li D; Schaub N; Guerin TM; Bapiro TE; Richards FM; Chen V; Talsania K; Kumar P; Gilbert DJ; Schlomer JJ; Kim SJ; Sorber R; Teper Y; Bautista W; Palena C; Ock CY; Jodrell DI; Pate N; Mehta M; Zhao Y; Kozlov S; Rudloff U
Mol Cancer Ther; 2021 Oct; 20(10):1926-1940. PubMed ID: 34376576
[TBL] [Abstract][Full Text] [Related]
16. ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.
Henry KE; Mack KN; Nagle VL; Cornejo M; Michel AO; Fox IL; Davydova M; Dilling TR; Pillarsetty N; Lewis JS
Mol Cancer Ther; 2021 Oct; 20(10):2026-2034. PubMed ID: 34349003
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
18. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15
Dominguez CX; Müller S; Keerthivasan S; Koeppen H; Hung J; Gierke S; Breart B; Foreman O; Bainbridge TW; Castiglioni A; Senbabaoglu Y; Modrusan Z; Liang Y; Junttila MR; Klijn C; Bourgon R; Turley SJ
Cancer Discov; 2020 Feb; 10(2):232-253. PubMed ID: 31699795
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
Dangi-Garimella S; Krantz SB; Barron MR; Shields MA; Heiferman MJ; Grippo PJ; Bentrem DJ; Munshi HG
Cancer Res; 2011 Feb; 71(3):1019-28. PubMed ID: 21148071
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
